Seta Clinic Group, Chiyoda-ku, Tokyo, Japan.
Anticancer Res. 2013 Jul;33(7):2957-63.
A 35-year-old female with scirrhous stomach cancer (stage IV) was treated with a combination of 5-aminolevulinic acid (ALA), sodium dichloroacetate (DCA), hyperthermotherapy, and immunotherapy as terminal care. The patient survived for one year and seven months, during which her quality of life was markedly improved and she returned to work. The patient was diagnosed with poorly-differentiated adenocarcinoma and progressive signet-ring cell carcinoma, accompanied by left ovarian metastasis, peritoneal dissemination, and right hydronephrosis stage IV, and treated with combination chemotherapy with tegafur-gimeracil-oteracil potassium (TS-1) and docetaxel. Oral ALA and DCA were concomitantly administered at 50 mg each three times a day (150 mg/day, respectively). In addition, hyperthermotherapy using thermotron was concomitantly performed at 2- to 3-week intervals. Cellular immunotherapy with αβ T- and immature dendritic cells was also performed. The disease did not progress for 11 months, her quality of life was markedly improved, and she was able to return to work. However, the signs of enlargement of the ovarian metastatic lesion were noted later, for which chemotherapy with four cycles of second-line paclitaxel and a half dose of irinotecan and cisplatin as third-line treatment were performed. Combination of ALA/DCA, hyperthermotherapy, and cellular immunotherapy may be a low-invasive palliative therapy superior in maintaining quality of life of tumor-bearing terminally ill individuals.
一位 35 岁女性患有硬癌性胃癌（IV 期），作为终末期治疗，接受了 5-氨基乙酰丙酸（ALA）、二氯醋酸钠（DCA）、热疗和免疫疗法的联合治疗。该患者存活了一年零七个月，在此期间，她的生活质量显著提高并恢复了工作。患者被诊断为低分化腺癌和进行性印戒细胞癌，伴有左卵巢转移、腹膜扩散和右肾盂积水 IV 期，并接受替加氟-吉美嘧啶-奥替拉西钾（TS-1）和多西他赛联合化疗。同时给予口服 ALA 和 DCA，每天三次，每次 50mg（分别为 150mg/天）。此外，还每 2-3 周进行 thermotron 的热疗。同时进行 αβ T 细胞和不成熟树突状细胞的细胞免疫疗法。疾病没有进展 11 个月，患者的生活质量显著提高，并能够恢复工作。然而，后来发现卵巢转移病灶增大的迹象，因此进行了二线紫杉醇、伊立替康和顺铂的半剂量四线治疗四个周期的化疗。ALA/DCA、热疗和细胞免疫疗法的联合可能是一种低侵袭性的姑息治疗方法，可更好地维持肿瘤终末期患者的生活质量。
